11 apr: Europa/luk: Nådesløs afstraffelse af Nokia
12 apr: Selskabernes forventninger - torsdag den 12 april
11-04-2012 23:54:00

UPDATE: Quest Diagnostics Names Rusckowski As President, CEO

Relateret indhold

--Quest names Philips executive as new CEO

--Stephen Rusckowski's appointment effective May 1

--Change could mark new course for Quest

(Adds analyst comments, updated share price, other information, in the second, fourth and fifth paragraphs.)

By Anjali Athavaley and Nathalie Tadena

Of DOW JONES NEWSWIRES

NEW YORK -(Dow Jones)- Quest Diagnostics Inc. (DGX) named Royal Philips Electronics NV (PHG, PHIA.AE) executive Stephen Rusckowski as its new president and chief executive, ending a six-month search for a successor to current CEO Surya Mohapatra.

Rusckowski's appointment is effective May 1, and he will join the company's board. Rusckowski has served as CEO of Philips Healthcare, Royal Philips' largest unit, since 2006. During his tenure, revenue at the unit increased to about EUR9 billion and 39% of Royal Philips' total revenue in 2011 from about EUR6B and 21% of revenue in 2005.

The management change could mark a new course for the company. Some decisions Quest made under Mohapatra--such as the acquisition of diagnostics company AmeriPath Inc. and an expansion into India--have been criticized by analysts.

"We knew this was going to get announced any day," said Art Henderson, health-care analyst at Jefferies & Co. "The investment community wasn't sure who the candidate would be. Who they have chosen is obviously somebody who was pretty instrumental in the growth at Philips."

Quest shares rose 1% to $60.20 in after-hours trading Wednesday. The stock is up 2.6% this year.

Quest, the largest diagnostic-testing company in the U.S. by revenue, had been hurt by a decline in doctor-office visits as consumers have reined in their health-care spending since the recession. Last year, the company unveiled a restructuring initiative to reduce its costs by $500 million over the next three years to help it meet profit targets. In October, the company initiated a search for a replacement for Mohapatra, who held the titles of chairman, president and CEO.

Quest also appointed lead director Daniel C. Stanzione as its new non-executive chairman.

"Steve Rusckowski is uniquely qualified to be chief executive officer of Quest Diagnostics," Stanzione said. "He has built an enviable track record in health care by successfully driving growth, both organically and through disciplined, effective acquisitions. His emphasis on operational excellence has enabled him to deliver consistently impressive results."

In January, Quest reported its fourth-quarter earnings rose 14% as the company saw higher testing revenue and improved margins.

-By Anjali Athavaley and Nathalie Tadena, Dow Jones Newswires; 212-416-4912; anjali.athavaley@dowjones.com

(END) Dow Jones Newswires

April 11, 2012 17:54 ET (21:54 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aktier/åbning: Genmab, FLS og Novo sender markedet i grønt

26-07-2016 09:13:11
En god nyhed til Genmab og et skulderklap til FLSmidth sender aktierne til vejrs på det danske aktiemarked tirsdag, hvor stemningen overordnet set er positiv.Ef..

Aktier/tendens: Genmab og FLSmidth kan løbe fra markedet

26-07-2016 07:46:11
På papiret gode nyheder kan trække Genmab og FLSmidth op på det danske aktiemarked tirsdag, hvor der umiddelbart er lagt op til mindre stigninger fra start.Det ..

GN/DNB: Ny strategi og produktlancering giver købsmulighed - NY

25-07-2016 13:30:01
Køb aktier i GN Store Nord, inden de gode nyheder begynder at komme hen over efteråret.Sådan lyder budskabet fra norske DNB, der spår et spændende efterår for p..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Genmab og FLSmidth kan løbe fra markedet
2
Mandagens aktier: Pandoras fald trak resten af C20 med ned
3
Amerikansk bank rygtes på vej mod salg og stiger stort
4
Nordea/Sydbank: Bekymret for udbytterne
5
Genmab: FDA giver Darzalex særlig status

Relaterede aktiekurser

Philips KON 24,40 0,5% Stigning i aktiekurs
Koninklijke Philips N.V... 26,61 0,0% Aktiekurs uændret
Quest Diagnostics Incorp.. 84,45 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. juli 2016 14:10:10
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160725.4 - EUROWEB7 - 2016-07-26 14:10:10 - 2016-07-26 14:10:10 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x